<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257035</url>
  </required_header>
  <id_info>
    <org_study_id>S-20100054</org_study_id>
    <nct_id>NCT01257035</nct_id>
  </id_info>
  <brief_title>Predictive Value of 18F-FAZA in Rectum Cancer</brief_title>
  <acronym>FAZA</acronym>
  <official_title>The Predictive Value of 18F-FAZA-PET/CT in Neoadjuvant Radiation for Patients With Locally Advanced Rectum Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to investigate 18F-FAZA-PETs role as predictor of
      response to neoadjuvant chemoradiation of locally advanced rectum cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The logistics of this trial (incl. supply of tracer) in connection with the patients' treatment
    course caused the inclusion rate to be very slow.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to chemoradiotherapy measured by TRG</measure>
    <time_frame>8 weeks after chemoradiation treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>From date of inclusion till date of verified recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>From date of inclusion till date of death by any cause</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Locally Advanced Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>18F-FAZA-PET/CT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-FAZA-PET/CT</intervention_name>
    <description>Contrast fluid injected prior to scan</description>
    <arm_group_label>18F-FAZA-PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced rectum cancer receiving preoperative radiation treatment and
        concomitant chemotherapy at the Dept. of Oncology, Vejle Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopatologically verified adenocarcinoma in the rectum

          -  T4 tumor eller T3 tumor &lt; 10 cm from the anus and &lt; 5 mm from the mesorectal fascie
             measured by MR scan. At the distal part of the rectum the distance to the mesorectal
             fascie is &lt; 5 mm and therefore all T3 tumors are included in this area

          -  Suitable for preoperative radiation and chemotherapy

          -  No distant metastases

          -  Age &gt;18 years

          -  Hematology ANC ≥1.5x10^9/l. Thrombocytes ≥ 100x10^9/l.

          -  Biochemistry Bilirubin ≤ 3 x UNL. ALAT ≤ 5 x UNL

          -  Creatinine ≤ UNL

          -  Contraception for fertile women

          -  Written and orally informed consent

        Exclusion Criteria:

          -  Other malignant disease within 5 years, excl. non-melanotic skin cancer

          -  Previous radiation treatment of the pelvis

          -  Pregnant or breastfeeding women

          -  Surgery within 6 weeks prior to enrollment

          -  Serious concurrent medical disease

          -  Enrollment in study &quot;A prospective observational study of patients with rectum cancer
             after concomitant radiation and chemotherapy&quot;, where the patients are potientially not
             operated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectum cancer</keyword>
  <keyword>FAZA</keyword>
  <keyword>18F-FAZA-PET/CT</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

